Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06493825

Mindfulness Application Effects on Mental Health Symptoms in Children With Severe Tinnitus and Misophonia

Children with "bothersome" tinnitus and misophonia have elevated anxiety and depression symptoms. The mainstay therapy for adults and children with these disorders is cognitive behavioral therapy (CBT). CBT resources are expensive and scarce for the pediatric population. Immersive virtual reality (IVR) has been shown in the adult population to be a proxy for CBT for several mental health disorders. There is sufficient published evidence that IVR is useful in treating adults with anxiety and depression disorders. However, the evidence in children in treating either anxiety and depression symptoms or disorder is scant. Our group views IVR application as a promising medical device to decrease anxiety and depression scores in children with tinnitus and misophonia disorders.

This is a randomized placebo control (single-blinded to the study subjects) study in which there will be a 2:1 ratio between the experimental and placebo subjects, receiving either active IVR or placebo exposure. A total of 30 subjects with 20 experimental (10 tinnitus, 10 misophonia subjects) and 10 placebo (5 tinnitus and 5 misophonia subjects) will enroll in this randomized clinical trial. Assessment of change of quality of life, anxiety and depression symptoms will be based on 5 validated instruments.

The 5 validated instruments are: Tinnitus Functional Index (TFI), Amsterdam Misophonia Scale (A-MIS-S), Pediatric Quality of Life PEDQL), Screen for Child Anxiety Related Emotional Disorders (SCARED) and Short Mood and Feelings Questionnaire (SMFQ).

Recruiting

Interested in participating?

Request Info

Key information

Age range

10 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's Hospital Colorado

Aurora, Colorado, 80218, United States

Location status: Recruiting

Location contact

Kenny H Chan, MD

CONTACT

[email protected]

720-777-8502

Kenny H Chan, MD

PRINCIPAL_INVESTIGATOR

About this study

Children with "bothersome" tinnitus and misophonia have elevated anxiety and depression symptoms. The mainstay therapy for adults and children with these disorders is cognitive behavioral therapy (CBT). CBT resources are expensive and scarce for the pediatric population. Immersive virtual reality (IVR) has been shown in the adult population to be a proxy for CBT for several mental health disorders. There is sufficient published evidence that IVR is useful in treating adults with anxiety and depression disorders. However, the evidence in children in treating either anxiety and depression symptoms or disorder is scant. Our group views IVR application as a promising medical device to decrease anxiety and depression scores in children with tinnitus and misophonia disorders.

This is a randomized placebo control (single-blinded to the study subjects) study in which there will be a 2:1 ratio between the experimental and placebo subjects, receiving either active IVR or placebo exposure. A total of 30 subjects with 20 experimental (10 tinnitus, 10 misophonia subjects) and 10 placebo (5 tinnitus and 5 misophonia subjects) will enroll in this randomized clinical trial. Assessment of change of quality of life, anxiety and depression symptoms will be based on 5 validated instruments.

The 5 validated instruments are: Tinnitus Functional Index (TFI), Amsterdam Misophonia Scale (A-MIS-S), Pediatric Quality of Life PEDQL), Screen for Child Anxiety Related Emotional Disorders (SCARED) and Short Mood and Feelings Questionnaire (SMFQ).

The primary outcome measures are the changes ot the pre-entry and post-entry scores of the 5 validated instruments at 2 weeks post-entry. In the experimental group, dose response will be measured between the 2- and 4-week results.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children between the ages of 10 to 18 years
  • All genders and ethnicities
  • Patients who meet criteria for "severe" symptoms of tinnitus and misophonia as scored by TIF and A-MISO-S

Exclusion criteria

  • Severe developmental delay as not to understand verbal instructions necessary to complete the VR application/sham exposure.
  • Severe visual impairment (refractive disorders are acceptable)
  • Patients with unilateral or bilateral hearing loss of any type.
  • History of seizure disorder

Treatment and study plan

Aurora Mindfulness app versus sham

Other

It would either immersive virtual reality exposure for the experimental group or non-immersive virtual reality exposure for the placebo group.

Primary outcomes

  1. Tinnitus Functional Index (TFI)

    Time frame: 2 weeks

    TFI measures the severity of tinnitus symptoms across several domains with a score range 0 to 90. The higher the score, the more dysfunction a subject is affected by tinnitus.

  2. Amsterdam Misophonia Scale (A-MIS-S)

    Time frame: 2 weeks

    A-MIS-S measures the severity of misophonia symptoms across several domains with a score range of 0-24. The higher the score, the more dysfunction a subject is affected by misophonia.

  3. Pediatric Quality of Life PedQL)

    Time frame: 2 weeks

    PedQL measures health-related quality of life of children with a range of 0 -100. The higher the score, the worse the health-related quality of life is.

  4. Screen for Child Anxiety Related Emotional Disorders (SCARED)

    Time frame: 2 weeks

    SCARED screens for anxiety disorder in children and it ranges from 0-82. The higher the score, the higher the likelihood a child might have an anxiety disorder.

  5. Short Mood and Feelings Questionnaire (SMFQ)

    Time frame: 2 weeks

    SMFQ measures depressive symptoms in children with a range of 0-26. The higher the score, the more depressive symptoms a child has.

  6. Tinnitus Functional Index (TFI)

    Time frame: 4 weeka

    TFI measures the severity of tinnitus symptoms across several domains with a score range 0 to 90. The higher the score, the more dysfunction a subject is affected by tinnitus.

  7. Amsterdam Misophonia Scale (A-MIS-S)

    Time frame: 4 weeks

    A-MIS-S measures the severity of misophonia symptoms across several domains with a score range of 0-24. The higher the score, the more dysfunction a subject is affected by misophonia.

  8. Pediatric Quality of Life PedQL)

    Time frame: 4 weeks

    PedQL measures health-related quality of life of children with a range of 0 -100. The higher the score, the worse the health-related quality of life is.

  9. Screen for Child Anxiety Related Emotional Disorders (SCARED)

    Time frame: 4 weeks

    SCARED screens for anxiety disorder in children and it ranges from 0-82. The higher the score, the higher the likelihood a child might have an anxiety disorder.

  10. Short Mood and Feelings Questionnaire (SMFQ)

    Time frame: 4 weeks

    SMFQ measures depressive symptoms in children with a range of 0-26. The higher the score, the more depressive symptoms a child has.

Secondary outcomes

  1. Satisfaction, acceptability and feasibility survey

    Time frame: 2 weeks

    The survey is in a 5-point Likert scale format with a range of very satisfied, satisfied, neutral, unsatisfied and very unsatisfied.

  2. Satisfaction, acceptability and feasibility survey

    Time frame: 4 weeks

    The survey is in a 5-point Likert scale format with a range of very satisfied, satisfied, neutral, unsatisfied and very unsatisfied.

Study contacts

Contact information is provided by the study sponsor or research team.

Kenny H Chan, MD

CONTACT

[email protected]

720-777-8502

Sponsors and collaborators

Lead sponsor

University of Colorado, Denver

Other

Registry information

Official study title

Effects of Immersive Virtual Reality Mindfulness Application on Quality of Life, Anxiety and Depression Symptoms in Children With Severe Tinnitus and Misophonia - A Pilot Study

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jul 10, 2024
Registry last updated
Apr 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.